| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An Exploratory Analysis from IRIS
|
Jacobson, Anne
|
|
2011
|
11 |
10 |
p. 23-24
|
artikel
|
| 2 |
Apixaban Superior to Warfarin for Prevention of SSE in Patients with AF: Results from ARISTOTLE
|
Vinall, Maria
|
|
2011
|
11 |
10 |
p. 11-12
|
artikel
|
| 3 |
Are Treatment Effects Different in Women?
|
Buckley, Rita
|
|
2011
|
11 |
10 |
p. 35-35
|
artikel
|
| 4 |
ASCOT-LLA: Statin Legacy Felt with Reduced Non-CV Death Eight Years after Trial End?
|
Jacobson, Anne
|
|
2011
|
11 |
10 |
p. 22-23
|
artikel
|
| 5 |
Benefits of Apixaban over Warfarin are Consistent, Irrespective of TTR
|
Vinall, Maria
|
|
2011
|
11 |
10 |
p. 12-13
|
artikel
|
| 6 |
Beyond the Guidelines: New Evidence in AF
|
Buckley, Rita
|
|
2011
|
11 |
10 |
p. 31-32
|
artikel
|
| 7 |
Controversial Issues in TAVI
|
Vinall, Maria
|
|
2011
|
11 |
10 |
p. 27-28
|
artikel
|
| 8 |
EMPHASIS-HF: An Analysis of the High-Risk Groups
|
Vinall, Maria
|
|
2011
|
11 |
10 |
p. 14-15
|
artikel
|
| 9 |
ESC Clinical Practice Guidelines — 2011 Update Overview
|
Vinall, Maria
|
|
2011
|
11 |
10 |
p. 8-10
|
artikel
|
| 10 |
EXAMINATION: Similar Outcomes with New-Generation DES Compared with BMS for Patients with Acute STEMI Undergoing PCI
|
Jacobson, Anne
|
|
2011
|
11 |
10 |
p. 20-21
|
artikel
|
| 11 |
IABP Do Not Reduce Infarct Size in Patients with STEMI without Cardiac Shock: The CRISP AMI Trial
|
Buckley, Rita
|
|
2011
|
11 |
10 |
p. 21-21
|
artikel
|
| 12 |
Increased Bleeding Risk with Concomitant Use of Antiplatelet Therapy: Dabigatran vs Warfarin
|
Vinall, Maria
|
|
2011
|
11 |
10 |
p. 24-25
|
artikel
|
| 13 |
Lipid Controversies: Beyond Statin Therapy and LDL
|
Buckley, Rita
|
|
2011
|
11 |
10 |
p. 29-30
|
artikel
|
| 14 |
New Observations from STICH
|
Jacobson, Anne
|
|
2011
|
11 |
10 |
p. 21-22
|
artikel
|
| 15 |
New Options for Improving DAPT and Stent Implantation
|
Jacobson, Anne
|
|
2011
|
11 |
10 |
p. 33-34
|
artikel
|
| 16 |
ONTARGET: Treatment Nonadherence Rapidly Increases CV Event Risk
|
Jacobson, Anne
|
|
2011
|
11 |
10 |
p. 26-26
|
artikel
|
| 17 |
Pitfalls in Troponin Evaluation
|
Vinall, Maria
|
|
2011
|
11 |
10 |
p. 34-35
|
artikel
|
| 18 |
Postprandial TG and Risk in Patients with CVD
|
Jacobson, Anne
|
|
2011
|
11 |
10 |
p. 17-20
|
artikel
|
| 19 |
Preventing CVD by Preventing Diabetes
|
Buckley, Rita
|
|
2011
|
11 |
10 |
p. 6-7
|
artikel
|
| 20 |
PURE: CV Drugs Underused for Secondary Prevention in Poor and Rural Populations
|
Jacobson, Anne
|
|
2011
|
11 |
10 |
p. 16-17
|
artikel
|
| 21 |
ROCKET-AF: Rivaroxaban vs Warfarin in Patients with Moderate Renal Insufficiency
|
Jacobson, Anne
|
|
2011
|
11 |
10 |
p. 25-26
|
artikel
|
| 22 |
Safety and Tolerability Darexaban in Patients with ACS: The RUBY-1 Trial
|
Vinall, Maria
|
|
2011
|
11 |
10 |
p. 13-14
|
artikel
|
| 23 |
The PRODIGY Trial – More Information about DAPT after DES Implantation
|
Buckley, Rita
|
|
2011
|
11 |
10 |
p. 15-16
|
artikel
|
Tijdschrift beschrijving